Evidence map›Paper›PMID 29438473›Full record

ArticleEndocrinology2018

In Uncontrolled Diabetes, Hyperglucagonemia and Ketosis Result From Deficient Leptin Action in the Parabrachial Nucleus.

Thomas H Meek, Miles E Matsen, Chelsea L Faber, Colby L Samstag, Vincent Damian, Hong T Nguyen, Jarrad M Scarlett, Jonathan N Flak, Martin G Myers, Gregory J Morton

Open access · bronzeAbstract read
In one paragraph

Article in Endocrinology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.5field-weighted citation impact, top 41% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Leptin Receptors in RIP-CreFrontiers in endocrinology · 2020
    Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Thomas H MeekUniversity of Washington Medicine Diabetes Institute, Department of Medicine, University of Washington, Seattle, Washington.
Miles E MatsenUniversity of Washington Medicine Diabetes Institute, Department of Medicine, University of Washington, Seattle, Washington.
Chelsea L FaberUniversity of Washington Medicine Diabetes Institute, Department of Medicine, University of Washington, Seattle, Washington.
Colby L SamstagUniversity of Washington Medicine Diabetes Institute, Department of Medicine, University of Washington, Seattle, Washington.
Vincent DamianUniversity of Washington Medicine Diabetes Institute, Department of Medicine, University of Washington, Seattle, Washington.
Hong T NguyenUniversity of Washington Medicine Diabetes Institute, Department of Medicine, University of Washington, Seattle, Washington.
Jarrad M ScarlettUniversity of Washington Medicine Diabetes Institute, Department of Medicine, University of Washington, Seattle, Washington.
Jonathan N FlakDepartment of Internal Medicine, University of Michigan, Ann Arbor, Michigan.
Martin G MyersDepartment of Internal Medicine, University of Michigan, Ann Arbor, Michigan.
Gregory J MortonUniversity of Washington Medicine Diabetes Institute, Department of Medicine, University of Washington, Seattle, Washington.
University of Washington · USUniversity of Michigan–Ann Arbor · US

Funding

Vector and Transgenic Mouse CoreP30DK017047 · NIDDK · UNIVERSITY OF WASHINGTON · PI REBECCA LUCY HULL-MEICHLE · 1986 to 2026
$41.4M
PILOT STUDY--CLINICAL NUTRITION RESEARCHP30DK035816 · NIDDK · UNIVERSITY OF WASHINGTON · PI Ellen A Schur · 1986 to 2026
$30.4M
Regional Pilot And Feasibility Study Grants ProgramP30DK020572 · NIDDK · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI Mehboob A Hussain · 2013 to 2026
$24.3M
Diabetes, Obesity and Metabolism Training ProgramT32DK007247 · NIDDK · UNIVERSITY OF WASHINGTON · PI GREGORY J MORTON, KRISTINA Marie UTZSCHNEIDER · 1986 to 2026
$10.0M
Neuroendocrine Control of Glucose MetabolismR01DK089056 · NIDDK · UNIVERSITY OF WASHINGTON · PI MORTON, GREGORY J · 2011 to 2024
$5.6M
Central and Peripheral Mechanisms of FGF1-Mediated Remission of Diabetic HyperglycemiaK08DK114474 · NIDDK · UNIVERSITY OF WASHINGTON · PI SCARLETT, JARRAD M · 2017 to 2021
$813k
Leica SP8 WWL Confocal MicroscopeS10OD016240 · OD · UNIVERSITY OF WASHINGTON · PI CATTERALL, WILLIAM A · 2014 to 2014
$581k
Identification of a neural circuit controlling blood glucoseF31DK113673 · NIDDK · UNIVERSITY OF WASHINGTON · PI FABER, CHELSEA LEIGH · 2017 to 2019
$116k
CNS Mechanisms Controlling Blood Glucose Levels in Uncontrolled Diabetes MellitusF32DK097859 · NIDDK · UNIVERSITY OF WASHINGTON · PI MEEK, THOMAS HARRIS · 2013 to 2014
$85k
NIDDK NIH HHS F31 DK113673NIDDK NIH HHS F32 DK097859NIDDK NIH HHS K08 DK114474NIDDK NIH HHS P30 DK017047NIDDK NIH HHS P30 DK020572NIDDK NIH HHS P30 DK035816NIDDK NIH HHS R01 DK089056NIDDK NIH HHS T32 DK007247NIH HHS S10 OD016240
6 · The paper itself

Abstract

Growing evidence implicates neurons that project from the lateral parabrachial nucleus (LPBN) to the hypothalamic ventromedial nucleus (VMN) in a neurocircuit that drives counterregulatory responses to hypoglycemia, including increased glucagon secretion. Among LPBN neurons in this circuit is a subset that expresses cholecystokinin (LPBNCCK neurons) and is tonically inhibited by leptin. Because uncontrolled diabetes is associated with both leptin deficiency and hyperglucagonemia, and because intracerebroventricular (ICV) leptin administration reverses both hyperglycemia and hyperglucagonemia in this setting, we hypothesized that deficient leptin inhibition of LPBNCCK neurons drives activation of this LPBN→VMN circuit and thereby results in hyperglucagonemia. Here, we report that although bilateral microinjection of leptin into the LPBN does not ameliorate hyperglycemia in rats with streptozotocin-induced diabetes mellitus (STZ-DM), it does attenuate the associated hyperglucagonemia and ketosis. To determine if LPBN leptin signaling is required for the antidiabetic effect of ICV leptin in STZ-DM, we studied mice in which the leptin receptor was selectively deleted from LPBNCCK neurons. Our findings show that although leptin signaling in these neurons is not required for the potent antidiabetic effect of ICV leptin, it is required for leptin-mediated suppression of diabetic hyperglucagonemia. Taken together, these findings suggest that leptin-mediated effects in animals with uncontrolled diabetes occur through actions involving multiple brain areas, including the LPBN, where leptin acts specifically to inhibit glucagon secretion and associated ketosis.

Indexed as

AnimalsBlood GlucoseDiabetes Mellitus, ExperimentalGlucagonInjections, IntraventricularInsulinKetosisLeptinMaleMiceNeuronsParabrachial NucleusRatsRats, WistarSignal TransductionBlood GlucoseGlucagonInsulinLeptin

Identifiers

PMID29438473
PMCPMC5939636
OpenAlexW2791730085

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.